Lyell Immunopharma (LYEL) Common Equity (2020 - 2026)
Lyell Immunopharma (LYEL) posted Common Equity of $273.7 million for Q1 2026, up 10.26% sequentially from $248.2 million in Q4 2025, and down 18.68% YoY from $336.5 million in Q1 2025.
Lyell Immunopharma (LYEL) Common Equity (2020 - 2026) Analysis & Trends
Lyell Immunopharma has reported Common Equity for 7 years, with the latest figure at $273.7 million in Q1 2026.
- Quarterly Common Equity fell 18.68% year-over-year to $273.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $273.7 million (down 18.68% YoY) and the FY2025 annual result came in at $248.2 million, down 35.17% from the prior year.
- Common Equity advanced to $273.7 million in Q1 2026 per LYEL's latest filing, from $248.2 million in the prior quarter.
- Over five years, Common Equity peaked at $881.2 million in Q1 2022 and troughed at $248.2 million in Q4 2025.
- A 5-year average of $579.1 million and a median of $603.2 million in 2024 frame the typical range for Common Equity.
- The sharpest annual moves came in 2022 and 2025: Common Equity jumped 363.81% in 2022, then slumped 47.23% in 2025.
- Over 5 years, Common Equity stood at $833.3 million in 2022, then retreated by 21.4% to $655.0 million in 2023, then slumped by 41.55% to $382.8 million in 2024, then sank by 35.17% to $248.2 million in 2025, then gained by 10.26% to $273.7 million in 2026.
- According to Business Quant data, Common Equity over the past three periods registered $273.7 million, $248.2 million, and $329.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Lyell Immunopharma | 326.39 Mn | 326.39 Mn | - | 233.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 233.82 Mn |
| Mar 31, 2026 | 273.67 Mn |
| Dec 31, 2025 | 248.20 Mn |
| Sep 30, 2025 | 329.12 Mn |
| Jun 30, 2025 | 298.92 Mn |
| Mar 31, 2025 | 336.52 Mn |
| Dec 31, 2024 | 382.82 Mn |
| Sep 30, 2024 | 530.70 Mn |
| Jun 30, 2024 | 566.50 Mn |
| Mar 31, 2024 | 603.16 Mn |
| Dec 31, 2023 | 654.95 Mn |
| Sep 30, 2023 | 697.57 Mn |
| Jun 30, 2023 | 736.86 Mn |
| Mar 31, 2023 | 783.83 Mn |
| Dec 31, 2022 | 833.25 Mn |
| Sep 30, 2022 | 820.03 Mn |
| Jun 30, 2022 | 868.04 Mn |
| Mar 31, 2022 | 881.25 Mn |
| Dec 31, 2021 | 929.79 Mn |
| Sep 30, 2021 | 986.47 Mn |